You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Protein Sequencing Tools for Biological Therapeutics

    SBC: PROTEIN METRICS INC            Topic: 400

    DESCRIPTION provided by applicant Mass spectrometry has become a method of choice for identifying and characterizing small quantities of proteins in complex mixtures However the ability to perform the identification in a high throughput fashion has depended on the availability of high quality protein sequence databases This means that proteins from organisms with unsequenced or poorly sequen ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. AFM based nanoscale IR Spectroscopy (AFM-IR) as a characterization platform for P

    SBC: Anasys Instruments Corp.            Topic: 300

    DESCRIPTION provided by applicant Anasys Instruments and Prof Lynne Taylor of Purdue propose to develop nanoscale chemical characterization capabilities for drug formulation research This project will build on successful Phase I research demonstrating feasibility of atomic force microscope based infrared spectroscopy AFM IR in pharmaceutical applications This Phase II research will advance ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 104

    DESCRIPTION provided by applicant Approximately of the population experiences elevated depressive symptoms Kubik et al Despite recent research suggesting that overall population mortality would be reduced by if the effects of subthreshold depression could be blocked completely the majority of individuals with elevated depressive symptoms never receive evidence based treat ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Latinos Kick Buts: Mobile Engagement and Cessation Support for Latino Smokers

    SBC: AGILE HEALTH INC            Topic: NIMHD

    DESCRIPTION provided by applicant Latinos Kick Buts Mobile Engagement and Cessation Support for Latino Smokers Latinos are less likely than non Hispanic whites to have access to health to have knowledge of existing smoking cessation resources to receive advice to stop smoking and to participate in smoking cessation programs Mobile technologies can dramatically enhance the reach of effectiv ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Gene and Oligonucleotide Delivery System

    SBC: MOLECULAR EXPRESS, INC            Topic: NCATS

    DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Dysbiotic Rebalancing with S. epidermidis Fermentation in Acne Vulgaris

    SBC: Surface Bioadvances, Inc.            Topic: NIAMS

    DESCRIPTION provided by applicant Dysbiosis refers to a condition with microbial imbalances within the human microbiome Yogurts are the best examples of using fermenting gut bacteria to rebalance the gut dysbiosis Our results demonstrate for the first time that Staphylococcus epidermidis S epidermidis a commensal bacterium of the human skin functions as a probiotic microorganism that em ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat rheumatoid arthritis RA Despite effectiveness many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of RA patients In addition juvenile arthritis patients suffer from th side effect of signi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Antibodies for Biofilm Infections

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government